Sign In
Buy NAVB
$0.0001
+0 (+0%)
At Close: Dec 30, 2025
Navidea Biopharmaceuticals, Inc. (NAVB) CEO Jed Latkin on Q4 2020 Results - Earnings Call Transcript
12:45am, Thursday, 25'th Mar 2021
Navidea Biopharmaceuticals, Inc. (NAVB) CEO Jed Latkin on Q4 2020 Results - Earnings Call Transcript
Navidea Biopharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results
04:21pm, Wednesday, 24'th Mar 2021
DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents an
DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents an
Navidea Biopharmaceuticals Strengthens Board of Directors with the Appointment of Malcolm Witter
07:30am, Monday, 28'th Dec 2020
DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents an
Is Navidea Biopharmaceuticals Inc (NAVB) A Good Stock To Buy?
06:34pm, Thursday, 26'th Nov 2020
Is Navidea Biopharmaceuticals Inc (NYSE:NAVB) a good place to invest some of your money right now? We can gain invaluable insight to help us answer that question by studying the investment trends of t
Navidea Biopharmaceuticals, Inc. (NAVB) CEO Jed Latkin on Q3 2020 Results - Earnings Call Transcript
11:05pm, Thursday, 12'th Nov 2020
Navidea Biopharmaceuticals, Inc. (NAVB) CEO Jed Latkin on Q3 2020 Results - Earnings Call Transcript
Navidea Biopharmaceuticals: Too Many Risks Involved
05:15pm, Monday, 14'th Sep 2020
Shares of Navidea Biopharmaceuticals have risen this year thanks to the positive results from its Phase 2 trial.
Navidea Biopharmaceuticals, Inc. (NAVB) CEO Jed Latkin on Q2 2020 Results - Earnings Call Transcript
11:13pm, Friday, 14'th Aug 2020
Navidea Biopharmaceuticals, Inc. (NYSEMKT:NAVB) Q2 2020 Results Earnings Conference Call August 13, 2020, 5:00 pm ET Company Participants Jed Latkin - Chief Executive Officer, Chief Financial Officer
Navidea Biopharmaceuticals Reports Second Quarter and Year-to-Date 2020 Financial Results
08:09pm, Thursday, 13'th Aug 2020
Navidea Biopharmaceuticals, Inc. (NYSE American:NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced it
Jubilant Radiopharma and Navidea Biopharmaceuticals Sign Binding Memorandum of Understanding for Commercialization Partnership
01:08pm, Monday, 10'th Aug 2020
Jubilant Radiopharma, a business unit of Jubilant Pharma Limited and Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) announced today that both companies have signed a binding memorandum of understan
Navidea Biopharmaceuticals Signs Binding Framework for Commercialization Partnership with Jubilant Radiopharma
11:30am, Monday, 10'th Aug 2020
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, is pleased to ann
Navidea Biopharmaceuticals Signs Binding Framework for Commercialization Partnership with Jubilant Radiopharma
12:00am, Monday, 10'th Aug 2020
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnosti
Navidea Biopharmaceuticals to Host Second Quarter 2020 Earnings Conference Call and Corporate Update
08:15pm, Thursday, 06'th Aug 2020
Navidea Biopharmaceuticals, Inc. (NYSE American:NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced it
Navidea Biopharmaceuticals to Host Second Quarter 2020 Earnings Conference Call and Corporate Update
12:00am, Thursday, 06'th Aug 2020
Navidea Biopharmaceuticals, Inc. (NYSE American:NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic
NEW YORK, NY / ACCESSWIRE / August 5, 2020 / Fields Kupka & Shukurov LLP is investigating potential breach of fiduciary duty claims involving the board of directors of Navidea Biopharmaceuticals, Inc.
